Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Debt (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Non-Current Debt for 7 consecutive years, with $1.5 million as the latest value for Q4 2022.

  • Quarterly Non-Current Debt fell 60.72% to $1.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2022, down 60.72% year-over-year, with the annual reading at $1.5 million for FY2022, 60.72% down from the prior year.
  • Non-Current Debt hit $1.5 million in Q4 2022 for Aptevo Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $25.2 million in Q3 2020 to a low of $1.5 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $11.1 million across 5 years, with a median of $9.3 million in 2018.
  • Biggest five-year swings in Non-Current Debt: surged 38.93% in 2019 and later tumbled 84.08% in 2021.
  • Year by year, Non-Current Debt stood at $19.3 million in 2018, then grew by 1.45% to $19.6 million in 2019, then increased by 2.54% to $20.1 million in 2020, then tumbled by 81.51% to $3.7 million in 2021, then plummeted by 60.72% to $1.5 million in 2022.
  • Business Quant data shows Non-Current Debt for APVO at $1.5 million in Q4 2022, $1.9 million in Q3 2022, and $2.4 million in Q2 2022.